Treeprasertsuk Sombat, Björnsson Einar, Sinakos Emmanouil, Weeding Emma, Lindor Keith D
Sombat Treeprasertsuk, Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
World J Gastrointest Pharmacol Ther. 2013 Aug 6;4(3):61-8. doi: 10.4292/wjgpt.v4.i3.61.
To study the outcomes of primary sclerosing cholangitis (PSC) patients with ulcerative colitis (UC) undergoing colectomy.
We identified 193 patients with PSC and UC undergoing colectomy at the Mayo Clinic (Rochester, MN, United States), between January 1, 1995 and December 31, 2008 using a computerized record system. Eighty-nine patients were excluded due to unclear diagnosis, liver transplantation prior to colectomy, age less than 18 years, inadequate follow-up data or known cases of cholangiocarcinoma. We retrospectively reviewed data from patient medical records. Clinical information, date of colectomy, preoperative and follow-up liver tests and pathological findings of the colon were reviewed. The Mayo risk score at baseline was calculated to obtain survival estimates for up to 4 years of follow-up. The primary endpoint was defined by the presence of all-cause mortality and/or liver decompensation requiring liver transplantation. All patients who did not have a clinical note on December 31, 2008 were considered as patients with an incomplete follow-up unless they reached a study endpoint (death or underwent liver transplantation) prior to that date. The study was approved by the Institutional Review Boards of the Mayo Clinic.
Of the 2441 patients with PSC observed in this period, 104 patients (4.3%) had UC and underwent colectomy and were included. The median age was 43.2 years, and 67% were male. The leading indications for colectomy were severe colonic inflammation (49%), the presence of colonic dysplasia during routine surveillance (42%) and bowel perforation (3%). Twenty-six patients were lost to follow-up after a median duration of 3.9 years. The remaining 78 patients included 52 patients (66.7%) who were followed for a median duration of 5.5 years and 26 patients (33.3%) who developed primary endpoints including death (n = 13) or underwent liver transplantation (n = 13) with a median follow up of 2.6 years. For the secondary endpoint, the liver complications within 1 mo following the colectomy were found in 9 patients (8.6%) and included worsening liver tests (n = 3), liver failure requiring liver transplantation (n = 2), acute cholangitis (n = 3) and right hepatic vein thrombosis with hepatic infarct (n = 1). A multivariate logistic analysis demonstrated that only lower platelet count and lower albumin level preoperatively were significantly associated with more primary endpoints (OR = 0.99 and 0.05 respectively).
One third of patients with PSC and UC undergoing colectomy died or underwent liver transplantation within 2.6 years. PSC patients with lower platelet counts and lower albumin levels were significantly more likely to have a poorer outcome.
研究原发性硬化性胆管炎(PSC)合并溃疡性结肠炎(UC)患者行结肠切除术的预后。
我们使用计算机化记录系统,在1995年1月1日至2008年12月31日期间,识别出在梅奥诊所(美国明尼苏达州罗切斯特)行结肠切除术的193例PSC合并UC患者。89例患者因诊断不明确、结肠切除术前肝移植、年龄小于18岁、随访数据不充分或已知胆管癌病例而被排除。我们回顾性地审查了患者病历中的数据。审查了临床信息、结肠切除日期、术前和随访肝功能检查以及结肠的病理结果。计算基线时的梅奥风险评分,以获得长达4年随访的生存估计。主要终点定义为全因死亡率和/或需要肝移植的肝失代偿。所有在2008年12月31日没有临床记录的患者,除非在此日期之前达到研究终点(死亡或接受肝移植),否则均被视为随访不完整。该研究获得了梅奥诊所机构审查委员会的批准。
在此期间观察到的2441例PSC患者中,104例(4.3%)合并UC并行结肠切除术,被纳入研究。中位年龄为43.2岁,67%为男性。结肠切除的主要指征为严重结肠炎症(49%)、常规监测时存在结肠发育异常(42%)和肠穿孔(3%)。26例患者在中位随访3.9年后失访。其余78例患者中,52例(66.7%)中位随访5.5年,26例(33.3%)出现主要终点,包括死亡(n = 13)或接受肝移植(n = 13),中位随访2.6年。对于次要终点,结肠切除术后1个月内9例(8.6%)出现肝脏并发症,包括肝功能检查恶化(n = 3)、需要肝移植的肝衰竭(n = 2)、急性胆管炎(n = 3)和右肝静脉血栓形成伴肝梗死(n = 1)。多因素逻辑分析表明,术前仅较低的血小板计数和较低的白蛋白水平与更多的主要终点显著相关(分别为OR = 0.99和0.05)。
三分之一的PSC合并UC行结肠切除术的患者在2.6年内死亡或接受肝移植。血小板计数较低和白蛋白水平较低的PSC患者预后明显较差。